Adempa-M Tablet 5 mg + 500 mg is a combination oral antidiabetic medication formulated with Empagliflozin 5 mg and Metformin Hydrochloride 500 mg. It is indicated for the management of type 2 diabetes mellitus in adults whose blood glucose levels are not adequately controlled with lifestyle modification or single-drug therapy. This dual-action formulation targets different pathways involved in glucose regulation, providing comprehensive glycemic control.

Adempa-M is intended to be used alongside a balanced diet, regular physical activity, and routine monitoring of blood glucose levels. The combination enhances treatment convenience by delivering two effective medicines in a single tablet.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Empagliflozin 5 mg

• Metformin Hydrochloride 500 mg

Mechanism of Action

Adempa-M combines two well-established antidiabetic agents with complementary mechanisms:

Empagliflozin
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It works by blocking glucose reabsorption in the kidneys, allowing excess glucose to be excreted through urine. This insulin-independent action lowers both fasting and postprandial blood sugar levels and may also contribute to modest weight loss and blood pressure reduction.

Metformin Hydrochloride
Metformin is a biguanide that primarily reduces hepatic glucose production (gluconeogenesis). It also improves insulin sensitivity and enhances peripheral glucose uptake. Metformin does not stimulate insulin secretion, helping to minimize the risk of hypoglycemia when used alone.

Together, these medications provide effective and sustained glycemic control by addressing both increased glucose production and impaired glucose elimination.

Indications

Adempa-M Tablet 5 mg + 500 mg is indicated for:

• Management of Type 2 Diabetes Mellitus

• Patients inadequately controlled with metformin alone

• Patients requiring combination therapy for improved glycemic control

• Use as part of a comprehensive diabetes treatment plan including diet and exercise

Benefits

• Dual Mechanism of Action: Controls blood sugar through kidney and liver pathways.

• Improved HbA1c Reduction: Helps achieve long-term glycemic targets.

• Weight Management Support: May assist in modest weight reduction.

• Cardiovascular Support: Empagliflozin has demonstrated cardiovascular benefits in eligible patients.

• Low Hypoglycemia Risk: When not combined with insulin or insulin secretagogues.

• Convenient Combination Tablet: Enhances patient adherence.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

The dosage should be determined by a healthcare professional based on individual glycemic status and renal function. It is generally taken once or twice daily with meals to reduce gastrointestinal side effects associated with metformin.

Patients should maintain adequate hydration and undergo regular monitoring of blood glucose, HbA1c, and kidney function.

Safety and Precautions

• Not recommended for Type 1 diabetes or diabetic ketoacidosis.

• Use cautiously in patients with renal impairment.

• May increase the risk of urinary tract infections and genital infections.

• Metformin may cause mild gastrointestinal discomfort, especially at the start of therapy.

• Rare cases of lactic acidosis have been reported with metformin; immediate medical attention is required if symptoms such as muscle pain, breathing difficulty, or unusual fatigue occur.

Adempa-M Tablet should be used under medical supervision. Patients should inform their healthcare provider about all current medications and medical conditions before initiating treatment.